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Dose-limiting neurotoxicity in a phase I study of
penclomedine (NSC 388720, CRC 88.04), a synthetic
aopicoline derivative, administered intravenously
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Summary 3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine (penclomedine, NSC 338720, CRC 88-04) is an a-picoline derivative with
anti-tumour activity in preclinical models. Penclomedine administration by 1-h intravenous infusion on 5 consecutive days was repeated
3 weekly in the absence of dose-limiting toxicity (DLT) or disease progression. Five dose levels were investigated (22.5-340 mg m-2 day-').
Eight men and eight women were entered, median age 59 years (range 39-73 years), with good performance status (ECOG 0/1) in 11
patients. A total of 13 out of 16 patients had received previous chemotherapy. Common toxicity criteria grade (CTCg) II vomiting was recorded
at all dose levels. Neurotoxicity (cerebellar ataxia and dizziness) was the DLT, CTCg IlIl toxicity occurring in three out of three patients treated
at 340 mg m-2 day-'. CTCg IlIl dizziness was noted in one out of three patients at 250 mg m-2 day-1. Neurotoxicity developed during the 1-h
infusion and persisted for a variable period (maximum 5 h) after infusion. Prophylactic antiemetic drugs appeared to reduce associated
vomiting but did not prevent ataxia. No antiproliferative toxicities were noted and no anti-tumour responses were documented. Penclomedine
pharmacokinetic studies confirmed preclinical evidence of extensive apparent distribution (931 m-2) and rapid clearance (411 h-1m-2). Purkinje
cell loss has been identified in preclinical models after intraperitoneal administration (O'Reilly et al, 1996a) and further clinical development of
penclomedine will focus on oral administration.
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Penclomedine (3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl}-
pyridine) was originally synthesized by Helen K Tobol, Dow
Chemical, USA, as part of a programme to develop effective
herbicides. It was identified as apotential anti-tumour agent by the
NCI in vivo P388 leukaemia prescreen. After evidence of good
activity against murine and human breast tumours, mouse CD8F,
mammary carcinoma and human MX-1 mammary tumour
xenograft (Plowman et al, 1989), penclomedine was selected for
further studies and subsequent clinical development. The mecha-
nism of action of penclomedine is unclear, although studies have
been performed that suggest that it undergoes metabolism to yield
reactive species thatbind to DNA (Plowman et al, 1989; Reid et al,
1992; Benvenuto et al, 1995.)
Penclomedine is poorly soluble in water but soluble in non-
polar solvents and lipids (Prankerd et al, 1989). Therefore, an
experimental formulation of penclomedine as a 10% oil in water
emulsion was developed for intravenous (i.v.) administration.
Using this formulation, penclomedine was active against the
advanced stage MX-1 mammary carcinoma: oral treatment with
doses of 135 mg kg-' day-' for 5 days resulted in ten out of ten
tumour-free survivors. The potency increased after intraperitoneal
administration and the drug was most potent when administered
i.v. (Harrison et al, 1991). No clear schedule dependency was been
observed with the oral administration of penclomedine, although
prolonged treatment appeared to be more effective than a single
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dose. Single treatments were effective when administered intra-
venously, but the dose used in a rapid bolus push was limited by
acute lethality. Repeated dose scheduling was more effective and
enabled administration ofa greater total dose.
Penclomedine has also been tested in drug-resistant cell lines
(doxorubicin, vincristine, cisplatinum, methotrexate, Ara-C and
5-FU) including the multidrug-resistant (MDR) phenotype. It was
found to have equivalent activity in both resistant and wild-type
cell lines. An AMSA-resistant line also appeared to be collaterally
sensitive to penclomedine but an L-PAM-resistant line was also
resistant to penclomedine (Harrison et al, 1991).
Pharmacokinetic data from mice indicate a rapid clearance
(114 ml min-m m-2), short half-life (69 min) and a large volume of
distribution (4.8 1 m-2) ofthe parent drug (Reid et al, 1992). Studies
with radiolabelled penclomedine demonstrated extensive metabo-
lism after both i.v. and oral administration. In vitro metabolism
studies have indicated that penclomedine is subject to metabolism
under both oxidative and reductive conditions (Reid et al, 1992).
Preclinical toxicology studies were performed in mice,
rats, and dogs. In mice, the maximum tolerated dose (MTD) was
150 mg kg-' (450 mg m-2) as a single i.v. dose and 80 mg kg-' day-'
(240 mg m-2day-'; total dose 1200 mg m-2) on adaily x 5 schedule.
Dose-limiting toxicities were neurological (single dose schedule)
and bone marrow suppression (daily x 5 schedule) (personal
communication, AC Smith, Toxicology and Pharmacology Branch,
DCT, NCI). After a single 5-h infusion in beagle dogs, the MTD
was 90 mg kg-', producing reversible myelosuppression. Higher
dosages were associated with dose-limiting neurotoxicity (Dixit et
al, 1992). Plasma penclomedine concentrations of 6-9 gg mi'
were achieved at the 90 mg kg-' dose level.
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The aims of this phase I study were: (a) to determine the MTD
of penclomedine when administered i.v. once daily for 5 days
every 21 days; (b) to identify the toxicity profile ofpenclomedine
and to determine whether this is predictable, tolerable and
reversible, and to define dose-limiting toxicities in patients; (c) to
determine thepharmacokinetics ofpenclomedine at different dose
levels; (d) to define a safe dose forsubsequent phase II studies of
anti-tumour activity; and (e) to observe and record any possible
therapeutic effectiveness ofpenclomedine.
MATERIALS AND METHODS
This was an open non-randomizedstudy with dose escalation that
continued until the dose-limiting toxicity was defined. A
minimum of three patients were treated at each dose level. Before
entry into the study all patients had a histologically confirmed
diagnosis ofmalignancy for which there was no alternative effec-
tive therapy. All patients were required to give written informed
consent. Before commencing the study ethical approval was
obtained from the Medicine and Clinical Oncology Research
Ethics Sub-Committee of Lothian Health Board (ref. MCO/
105/92) and the study was conducted according to the Helsinki
Declaration. This trial was conducted under the auspices of
the Cancer Research Campaign Phase I/II Clinical Trials
Committee.
Patients were eligible for inclusion ifthey were aged >18 years
and ofadequate performance status (< 2 on the ECOG scale) and
had a life expectancy> 12 weeks. Adequate bone marrow, hepatic
and renal function was required (WBC > 3 x 1091-1, platelet count
> 100 x 1091-1, serum creatinine < 120gmmol 1-l, bilirubin
<30gmol 1-1, and other liver function tests within twice the upper
limit of normal (unless known to be related to livermetastases)).
Patients were deemed ineligible in the event of pregnancy or
lactation, previous chemotherapy or radiotherapy within the last
4 weeks (6 weeks for nitrosoureas or mitomycin C), the presence
of anothernon-malignant disease that in theopinion ofthe investi-
gator was incompatible with this protocol, concurrent administra-
tion of another investigational drug, or cytotoxic, hormonal or
biological therapy. Patients with brain metastases orprimary brain
tumours were excluded and also patients with epilepsy or chronic
neurological disorders that might interfere with the assessment of
neurological toxicity.
Penclomedine was formulated as a de novo emulsion(in 100 ml:
soybeanoil, 100 mg; lecithin, 30 mg;glycerin 20 mg and waterfor
injection) and stored as intact vials under refrigeration (2-8°C).
Penclomedine emulsions were diluted up to 1:10 using 5%
dextrose solution. Nophysical or chemicalchanges were observed
when the above admixtures were stored at room temperature for
8 h in either glass bottles or plastic i.v. bags. Penclomedine was
supplied by the NCI DCT under the special foreign exemption
mechanism established with the FDA.
Penclomedine was administered as a 1-h infusion diluted in 5%
dextrose in water. Infusions were repeated daily x 5, and repeated
at 21-day intervals provided there was adequate recovery of any
drug-inducedtoxicity and no evidence ofdiseaseprogression.
The starting dose for this phase I study, 22.5 mg m-2day-1, was
based on one-tenth of the MTD in mice. Doses were to be
escalated depending on the incidence of toxicity. In the absence
of DLT dose levels of 22.5 mg m-2 day-1, 45.0 mg m-2 day-1,
74.0 mg m-2 day-1 and 112.5 mg m-2 day-' were planned with
subsequent escalation by 35% until the MTD was defined.
Three patients were to be entered at each dose level. After the
identification of significant (. CTC grade 3) toxicity, three
additional patients were to be evaluated. The MTD was defined as
the dose level at which one out of six patients suffered
2CTC grade 3 reversible non-haematological toxicity, or one dose
level lower than the DLT level. The DLT level was defined as
two out of six patients experiencing 2grade 3 non-haematological
toxicity. A minimum of four courses were evaluable at each dose
level before escalation. Treatment was discontinued before two
courses oftreatment ifthis was considered to be in the best interest
ofthe patient.
Before study entry a medical history, complete clinical exami-
nation including neurological examination and recording of the
height and weight of the patients was performed. A full blood
count, urea and electrolytes and liver function tests were
performedduring the study at weekly intervals. A chestradiograph
was also performed and other radiological investigations were
performed to assess disease status. Tumour responses were
assessed using standard UICC criteria.
PHARMACOKINETICS STUDIES
The plasma pharmacokinetics of penclomedine were assessed in
all patients entered into the phase I study. Plasma samples were
immediately spun and separated. Plasma was stored at-20°C until
assayed by high-performance liquid chromatography (HPLC).
Blood samples were taken before drug administration and at the
following times after the 1-h infusion: 5 min, 10min, 15 min,
30min,45min, 1 h,2h,4h,6h,8h, 16hand24h.
Penclomedine was measuredby HPLC, using the method previ-
ously published (Reid et al, 1992), after extraction using 100glof
DMSO, 500gl of plasma, 500glof chilled acetonitrile. This was
vortexed and left on ice for 30 min. It was then centrifuged
(microfuge) for 15 min and the supematant applied to the HPLC.
Ultraviolet detection was performed atthreewavelengths: 214 nm,
243 nm and 290 nm. Data were acquired stored and analysed
using the Millennium 2010 Chromatography System (Waters
Chromatography Division). The lower limit of detection was
20 ng ml-' penclomedine with intra- and interassay coefficients of
variation in quantitation of< 10%.
One- and two-compartment open linear models were fitted to
plasma concentration data using the algorithms included in the
computerprogram, ADAPT II(D'Argenio and Schumitsky, 1990).
Full data sets were fittedusing aweighted least-squares algorithm.
Parameter means and variance from five complete data sets were
used to construct a simple population model for use as Bayesian
priors to allow the analysis ofplasma profiles in which data were
sparse (lower dose levels).
RESULTS OF THE CLINICAL STUDY
Sixteen patients entered the study (male, eight; female, eight). The
median age was 59 years (range 39-73 years). ECOG performance
status (PS) was 0 or 1 in 11 patients. Fivepatients with PS =2 were
entered, including one out ofthree at the maximum dose assessed.
Non-small-cell lung carcinoma (fourpatients) and colorectal carci-
noma (fourpatients) were the most common tumour types entered.
13 out of 16patients had received previous chemotherapy.
The initial dose studied was 22.5 mg m-2day-' for 5 days and
after the successful treatment of three patients the dose was
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escalated. Five dose levels were tested in this dose-finding study:
22.5, 45, 150, 250 and 340 mg m-2 day-'. The accelerated escala-
tion from 45 to 150 mg m-2 day-1 was introduced as other NCI-
supported studies had commenced before this study and sufficient
data had accrued to allow us to escalate more rapidly without
compromising safety. At the maximum dose tested (340 mg m-2
day-') dose-limiting toxicity in the form of dizziness was encoun-
tered in three out ofthree patients (Table IA). Dizziness was asso-
ciated with cerebellar ataxia in many patients (Table IB). This was
not prevented by the prophylactic administration of prochloper-
azine, domperidone or benztropine. The incidence ofneurotoxicity
was clearly dose related and appeared to resolve shortly after
discontinuation of treatment in most patients. Neurotoxicity was
noted during the infusion ofpenclomedine and persisted for a vari-
able duration after the infusion was completed (maximum 5 h).
Nausea and/or vomiting was noted at the start dose and at all
subsequent dose levels (Table IC and D). Prophylactic antiemetics
were administered to all patients at dose levels . 250 mg m-2 day-'.
Antiproliferative toxicities such as myelosuppression or
mucositis were not noted during the course of this study. There
was also no evidence ofanti-tumour activity.
RESULTS OF THE PHARMACOKINETIC STUDIES
The plasma concentration profile ofthe parent drug (Figure 1) was
best described by an open two-compartment model. The two-
compartment model was described using two volume parameters
(V, and Vp), distributional clearance (Cl ) and total body clearance
(Cli). Pharmacokinetic parameters in individual patients are shown
in Table 2.
These results confirm the preclinical data from mice, in that
there is evidence of extensive distribution ofpenclomedine (mean
V + Vp = 931 m-2) and the initial distribution phase is rapid (t112c =
12 min), although the apparent elimination phase was more
prolonged (t,/2P = 2.4 h) than in the mice. Total body clearance
(Cl) did not vary with dose. In contrast to preclinical studies that
had shown evidence ofmetabolite formation in preclinical models
(Reid et al, 1992), metabolites were not detected in the plasma of
patients treated in this phase I study.
DISCUSSION
These data represent acompletedphase I and pharmacokinetic study
ofthe novel anti-cancer drug penclomedine. The dose-limiting toxi-
city was shown to be dizziness (and associatedcerebellarataxia) and
this occurred at a dose of 340 mg m-2 day-' in three out of three
patients. No antiproliferative toxicities (for example myelosuppres-
sion, mucositis) were observed, although these would have been
predicted from the preclinical studies. Also, there was no evidence
ofantitumour activity in this group ofpatients. The pharmacokinetic
analyses confirmed the preclinical data, in that there was extensive
apparent distribution and rapid clearance of penclomedine. In these
studies, no metabolites were detected in the patients' plasma.
In preclinical studies performed in dogs, doses ofpenclomedine
associated with plasma concentrations of 6-9 ,ug ml-' were not
associated with neurotoxicity, but after higher doses neurotoxicity
was dose limiting (Dixit et al, 1992). Figure 1 demonstrates that
plasma concentrations approaching 10 tg ml-' were achieved in a
patient receiving 340 mg m-2 who experienced neurotoxicity.
Myelotoxicity was also recorded in these preclinical studies, but
was not apparent in this clinical trial.
Table 1 Toxicities associated with the administration of penclomedine.
A neurotxicity -dizziness; B neurotoxicity - ataxia; C nausea; and D vomiting
A
Daily dose Number of patients at each CTC grade
(mg m-2) (dizziness)
0 1 2 3 4
22.5 3
45 3
150 3
250 1 2 1
340 3
B
Daily dose Number of patients at each CTC grade
(mg m-2) (ataxia)
0 1 2 3 4
22.5 3
45 3
150 3
250 4
340 3
C
Daily dose Number of patients at each CTC grade
(mg m-2) (nausea)
0 1 2 3 4
22.5 2 1
45 1 2
150 1 1 1
250 2 1 1
340 1 1 1
D
Daily dose Number of patients at each CTC grade
(mg m-2) (vomiting)
0 1 2 3 4
22.5 2 1
45 1 2
150 3
250 2 2
340 1 1 1
The incidence of cerebellar toxicity appeared to be related to
drug infusion and generally resolved spontaneously after discon-
tinuation of therapy. There were insufficient data to formally
assess relationships between pharmacokinetic parameters and
toxicity data. Whether prolongation of the infusion time would
circumvent the neurotoxicity was to be addressed in a protocol
modification. However, the NCI had also supported preclinical
studies of penclomedine in the rat in collaboration with scientists
at Johns Hopkins Cancer Center, Baltimore, USA. These studies
specifically investigated the neurotoxicity associated with
penclomedine and suggested that pathological changes were
visible in the cerebellum of rats treated with penclomedine by
intraperitoneal injection (single dose 2150 mg kg-') and that these
may be irreversible (O'Reilly et al, 1996a). Therefore, in the
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Figure 1 Plasma concentration in patient 10 after administration of
penclomedine (340 mg m-2) by i.v. infusion
interest of patient safety, all clinical studies of penclomedine
administered intravenously were discontinued and phase II studies
are not planned in the foreseeable future.
However, much of the preclinical anti-tumour activity data
accrued using penclomedine were after its oral administration.
Oral administration of penclomedine was similar to i.p. adminis-
tration in degree oftherapeutic effect and potency for treatment of
subrenal capsule xenograft of the human MX-1 mammary carci-
noma. Oral doses of 300 mg kg-' day-' on days 13, 17 and 21
resulted in complete regression ofall tumours for40 days after the
last treatment, when the experiment was terminated. In advanced
stage s.c. human H82 small cell lung carcinoma xenografts, oral
administration of 445 mg kg-' day-' penclomedine produced six
out of ten complete regressions and four out of ten partial regres-
sions (Harrison 1991).
The anti-tumour activity after oral administration of penclo-
medine is present, despite the apparent low oral bioavailability of
the parent compound [2% in mice (Reid et al, 1992)]. Also, there is
an apparent association between neurotoxicity and the plasma
concentration of the parent compound. As penclomedine is the
predominant chemical species found in rat brain (O'Reilly et al,
1996b), these data and other studies utilizing metabolites of
penclomedine (O'Reilly et al, 1996a) suggest that the activity of
the drug is related to its metabolites and the toxicity associated with
the parent compound. Therefore, the clinical evaluation ofpenclo-
medine continues, but using the oral route ofadministration.
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